The Angiogenesis Foundation

The Angiogenesis Foundation Chief Executive Officer Dr. William Li was honored as the Inaugural Recipient of the Dr. Andrew von Eschenbach Award

Retrieved on: 
Wednesday, January 24, 2024
Richard Nixon, Medical director, Science, Cancer, The Angiogenesis Foundation, Conference, Research, Disease, Government, FDA, Pharmaceutical industry

CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire-PRWeb/ -- The Angiogenesis Foundation announces that its Chief Executive Officer, President & Medical Director, and co-founder, Dr. William Li, has been chosen as the inaugural recipient of the Dr. Andrew von Eschenbach Award. This prestigious accolade was presented on January 17, 2024, at the Nixon Presidential Library in Yorba Linda, California, during the opening event of the third annual Nixon National Cancer Conference, which brought together leaders in government, academia, and medical centers to discuss the latest breakthroughs in cancer research and treatment.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2024 /PRNewswire-PRWeb/ -- The Angiogenesis Foundation announces that its Chief Executive Officer, President & Medical Director, and co-founder, Dr. William Li, has been chosen as the inaugural recipient of the Dr. Andrew von Eschenbach Award.
  • His leadership at The Angiogenesis Foundation and collaboration with colleagues worldwide have propelled transformative advancements for cancer research and treatment.
  • The Angiogenesis Foundation expresses its gratitude to the Richard Nixon Foundation for recognizing Dr. Li's outstanding contributions.
  • Dr. William Li and The Angiogenesis Foundation are honored by this prestigious recognition and will continue their commitment to advancing new and effective approaches to prevent, treat, and reverse cancer.

Lonestar Data Holding Unveils J.F. Honeycutt Mission Control for Lunar Disaster Recovery

Retrieved on: 
Tuesday, January 16, 2024
Cloud, Astronaut, Mission control center, Capcom, NASA, Advisory board, Kennedy Space Center, The Angiogenesis Foundation, Intuitive Machines, SpaceX, Management

ST. PETERSBURG, Fla., Jan. 16, 2024 /PRNewswire/ -- Lonestar Data Holding, a trailblazer in the intersection of Cloud and Space technologies, proudly announced the inauguration of the J.F. Honeycutt Mission Control at the Maritime and Defense Hub in St. Petersburg, Florida.

Key Points: 
  • Honeycutt Mission Control at the Maritime and Defense Hub in St. Petersburg, Florida.
  • Apollo 16 and CapCom for Apollo 11, and fellow Lonestar Advisory Board member, as the Mission Control Centers first video link to open MIssion Control.
  • Honeycutt Mission Control represents a significant milestone in Lonestar's commitment to advancing disaster recovery capabilities for the entire planet.
  • Honeycutt Mission Control and to contribute to the future of lunar exploration.

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

Retrieved on: 
Wednesday, November 29, 2023
Urine, Symrise, Regeneration, Avenanthramide, Research, Hand, McMaster University, Blood, MBA, Coenzyme Q10, The Angiogenesis Foundation, Animal, NATEX, Appetite, CZO, Completeness, Growth, Investment, Safety, YTD, YBG, Pharmaceutical industry

EDMONTON, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

Key Points: 
  • Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange.
  • Such formulations are to be resolubilized locally by Symrise and used for hair care and facial masks.
  • Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2023
    Total sales of $2,619,000 for the third quarter of 2023 and $7,983,000 for the first nine months of 2023 compared to $3,845,000 and $15,517,000 for the comparative periods in 2022.
  • Cash flows used in operations of $2,017,000 for the first nine months in 2023 vs cash generated from operations of $5,644,000 in 2022.

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, August 29, 2023
The Angiogenesis Foundation, Senior, Litre, Urine, Symrise, Clinical trial, MBA, Coenzyme Q10, Regulation and licensure in engineering, Trial of the century, YBG, Special Operations Executive, Regeneration, American Thoracic Society, McMaster University, Blood, Pharmacy, Growth, AVS, Dubai Health Authority, CZO, Safety, Wound healing, Pharmaceutical industry, Management, Dietary supplement, Medical device, Ready-mix concrete, Fine chemical, Cryptocurrency

EDMONTON, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2023.

Key Points: 
  • Further, over the past quarter we remained very active with our activities related to strategic corporate initiatives.
  • Stability studies are ongoing for the 30mg and 240mg pills formulation manufactured, packaged and labeled by Corealis Inc. GMP Manufacturing Services.
  • Studies showed statistically significant results characterizing the bioactivity of both Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration.
  • Financial Highlights for the Second Quarter and the Six-Month Period Ended June 30, 2022
    Sales of $1,869,000 for the second quarter of 2023 and $5,364,000 for the first six months of 2023 compared to $5,500,000 and $11,672,000 for the comparative periods in 2022.

Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation

Retrieved on: 
Tuesday, July 18, 2023
The Angiogenesis Foundation, MBA, Research, Inflammation, RNA, Gene expression, WHS, Dermatology, Regeneration, Annual general meeting, AV, Wound, CZO, BG, Skin, Wound healing, Pharmaceutical industry

EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives.

Key Points: 
  • EDMONTON, Alberta, July 18, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today the expansion of its collaboration with the Angiogenesis Foundation to conduct research on characterizing healing dynamics and molecular profiling of tissue regeneration stimulated by oat-derived bioactives.
  • This next research phase is an extension of previous studies demonstrating that Ceapro’s products have biological activity.
  • “A deeper understanding of how oat-derived bioactives improve healing performance at the cellular and molecular levels will allow for optimized product design and improved patient outcomes,” commented Dr. Vincent W. Li, Chief Scientific Officer of the Angiogenesis Foundation.
  • This is in line with our vision to expand our business model from an active ingredient provider to a life sciences company,” commented Gilles R. Gagnon, M.Sc., MBA, President and CEO of Ceapro.

The Angiogenesis Foundation Receives Landmark Philanthropic Gift to Advance Food as Medicine and Pioneer Dietary Angiogenesis

Retrieved on: 
Tuesday, July 11, 2023
Food, The Angiogenesis Foundation, Diet, TED (conference), Cancer, Research, Medicine, Science, Congress, Patient, United States Congress, Health, FDA, Disease, Wound healing, European Parliament Liaison Office with the US Congress, Pharmaceutical industry, The New York Times, Vatican

It propels the Foundation's pioneering work in utilizing food as medicine to prevent, treat, and reverse diseases through dietary angiogenesis.

Key Points: 
  • It propels the Foundation's pioneering work in utilizing food as medicine to prevent, treat, and reverse diseases through dietary angiogenesis.
  • Driven by a passion to explore the untapped healing potential of food, the Angiogenesis Foundation has been quietly revolutionizing the field of food as medicine.
  • This transformational philanthropic gift from Bancel Philanthropies propels the Angiogenesis Foundation into a position for leadership in this new frontier.
  • By uniting in this collective endeavor, the Foundation will shape the future where food becomes integral in societal health.

Ceapro to Participate in the Virtual Investor Summer Spotlight Series

Retrieved on: 
Wednesday, July 5, 2023
Science, The Angiogenesis Foundation, Virtual, CZO, Event, Pharmaceutical industry, Broadcasting

EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.

Key Points: 
  • EDMONTON, Alberta, July 05, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.
  • A live video webcast of the presentation will be available on the Events page of the Investors section of the Company’s website ( ceapro.com ).
  • A webcast replay will be available two hours following the live presentation and will be accessible for 90 days.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Thursday, May 25, 2023
GMP, Avenanthramide, Senior, Administration, Safety, Symrise, TSX Venture Exchange, Clinical trial, EPCM, G&A, MBA, Coenzyme Q10, Regulation and licensure in engineering, Trial of the century, YBG, Special Operations Executive, Regeneration, Ethics, Mask, The Angiogenesis Foundation, McMaster University, Organic acid, Pharmacokinetics, Investment, ALG, Mouse, Hand, Montreal Heart Institute, CZO, Skin, Technical, Wound healing, Pharmaceutical industry, Tolerability

EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • “Our team significantly advanced toward several key milestones related to new product development as well as strategic corporate initiatives.
  • Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
  • Announced positive results from animal studies conducted by Angiogenesis Foundation on a wound healing model.
  • Financial Highlights for the First Quarter Ended March 31, 2023
    Total sales of $3,500,000 for the first quarter of 2023 compared to $6,172,000 for the comparative period in 2022.

Ceapro Announces Positive Findings Demonstrating Oat Derived Beta Glucan and Avenanthramides Promote Wound Healing and Tissue Regeneration

Retrieved on: 
Wednesday, May 3, 2023
University, The Angiogenesis Foundation, Microcirculation, Progenitor cell, Scar, AVE, Research, Inflammation, Dermatology, Regeneration, AV, Mouse, Architecture, CZO, Wound healing, Pharmaceutical industry, Medical imaging

EDMONTON, Alberta, May 03, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today positive results from a research collaboration with the Angiogenesis Foundation (“Foundation”) conducted with colleagues at the University of Arizona. The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration.

Key Points: 
  • The aim of this study was to assess the in vivo bioactivity of Ceapro products on angiogenesis, wound healing, tissue repair, and regeneration.
  • Tissue analysis revealed that:
    1% AVE treatment resulted in decreased tissue inflammation and the healed tissue had less scarring and an architecture more resembling normal tissue compared to that of scar tissue after control treatment.
  • The researchers concluded that oat-based bioactives BG and AV exhibited potential to improve regenerative wound healing, reduce inflammation, promote angiogenesis, and reduce scar formation.
  • Gilles Gagnon, President and CEO of Ceapro, stated, “We are excited with these positive results showing efficacy of our two value drivers beta glucan and avenanthramides.

Ceapro Announces Data from Research Collaboration with the Angiogenesis Foundation to be Presented at the 2023 Annual Meeting of the Wound Healing American Society

Retrieved on: 
Wednesday, March 8, 2023
Wound healing, National Harbor, Maryland, The Angiogenesis Foundation, Inflammation, Mouse, Conference, Wound, Annual general meeting, WHS, CZO, Medical imaging, Pharmaceutical industry

EDMONTON, Alberta, March 08, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled “Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms,” has been accepted for a presentation at the Annual Meeting of the Wound Healing Society (WHS) to be held at the National Harbor, MD Conference Center between April 26-29, 2023.

Key Points: 
  • – Oral presentation to highlight unique results from pre-clinical studies characterizing the in vivo bioactivity of Ceapro’s oat-derived bioactive products on angiogenesis, wound healing and tissue regeneration –
    EDMONTON, Alberta, March 08, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that the abstract titled “ Application of Avena Sativa Derived Therapeutics β-Glucan and Avenanthramide Accelerate Wound Healing in Mice Via Angiogenic and Anti-inflammatory Mechanisms ,” has been accepted for a presentation at the Annual Meeting of the Wound Healing Society (WHS) to be held at the National Harbor, MD Conference Center between April 26-29, 2023.
  • The data to be presented springs from the research collaboration between The Angiogenesis Foundation and Ceapro demonstrating that oat-based bioactives beta glucan and avenanthramides have efficacy to reduce scar formation, inhibit inflammation, recruit stem cells, and stimulate angiogenesis.
  • For more information about the conference, please visit the event website here .